Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Leans Into Health Care and AI Plumbing

The biggest buys cluster around two themes: a decisive upgrade of health care and a push further down the AI and cloud plumbing stack.

On the health side, they didn’t nibble — they swung:

• AZN: A brand-new AstraZeneca position at 2.29% (about $2.51B) is a statement that biopharma is back in favor. They’re stepping in slightly below their $190.5 average cost with the position modestly underwater, suggesting they’re early by design rather than chasing momentum.
• JNJ: Johnson & Johnson is more than doubled, up 117.5% in shares and roughly +$815.0M, taking it to 1.38%. That’s a clear vote for diversified, litigation-de-risked pharma as a core ballast.
• LLY, EW, MCK: Eli Lilly (+28.3% in shares), Edwards Lifesciences (+65.7%), and McKesson (+30.1%) round out a build-out across obesity, devices, and drug distribution — a broad bet on health care volume growth rather than a single binary drug.

On the AI/cloud infrastructure side, they’re moving beyond the obvious frontmen:

• ARM: A 339.9% ramp in Arm, adding about $1.10B, says they see CPU and custom silicon demand as a long runway, not a one-cycle trade.
• NET: Cloudflare’s position explodes by 533.1% in shares, with roughly $782.3M added — an explicit claim that network security and edge compute are structural winners in AI-era internet traffic.
• ANET: Arista Networks gets a 131.3% boost (~$580.2M), capturing the switch-and-router bottleneck in AI data centers.
• META, AAPL: Meta (+37.2% in shares, +$586.0M) and Apple (+8.3%, +$416.5M) are being leaned into as platform beneficiaries of AI and services, not trimmed despite big gains.

They’re also adding industrial and cyclical teeth around real-world capex:

• URI: United Rentals shares surge 556.0%, adding about $573.8M. That’s a clear macro call on sustained construction and equipment demand.
• CAT and PWR: Increases in Caterpillar (+18.8%) and Quanta (+7.2%) extend that theme into machinery and grid/infrastructure services.

The common thread: pay up for assets that either compound through multiple macro regimes (pharma, devices) or sit in the critical path of AI build-out and infrastructure renewal.

The sell list is not a panic exit from risk; it’s a reallocation away from broad, well-owned winners and more cyclical or rate-sensitive exposures.

The biggest funding sources sit in established tech and financials:

• MSFT and AMZN: Microsoft is cut -13.7% (about -$692.2M) and Amazon -12.6% (-$509.9M). Both remain core positions, but Dz Bank is clearly comfortable turning a chunk of almost-doubled capital in Microsoft and sizable gains in Amazon into dry powder for less fully-priced names.
• STX: Seagate is slashed by -33.2% in shares, freeing roughly $703.7M while still sitting on a huge 226.4% gain vs. cost — classic profit-taking in a cyclical storage play after a big run.

Financials are being pared back in favor of more idiosyncratic growth and defensives:

• JPM and BAC: JPMorgan (-17.2%, -$461.1M) and Bank of America (-15.4%, -$294.2M) see meaningful trims as Finance sector weight falls from 11.35% to 9.67%. They’re not abandoning banks, but they’re acknowledging that the easy recovery trade is behind us.
• AXP: American Express is also reduced by -15.4%, another nod to consumer credit and rate risk.

Elsewhere, they’re cutting into more challenged or less differentiated health and consumer names:

• BSX and TMO: Boston Scientific (-28.6%, -$333.3M) and Thermo Fisher (-17.5%, -$303.1M) are notable health care trims, both sitting near or below cost. Dz Bank is essentially swapping these more fully owned med-tech names into pharma and devices where they see better asymmetry.
• SHW and KO: Sherwin-Williams (-25.4%, -$295.3M) and Coca-Cola (-21.5%, -$233.8M) are dialed back, signaling less enthusiasm for rate- and housing-sensitive paints and low-growth staples at rich multiples.

Taken together, the sells look like housekeeping: crystallizing outsized gains, reducing broad beta, and recycling into more targeted, thematically aligned exposure.

Tech remains the empire here, but it’s an empire under active management. Technology’s weight edges down from 44.46% to 43.13%, not because they’ve lost faith in AI, but because they’re narrowing focus from broad megacap software into semis, networking, and select cloud names.

That freed-up capital is marching decisively into health care. Sector weight more than doubles from 5.57% to 10.02%, driven by the new AstraZeneca stake plus big adds to Johnson & Johnson, Eli Lilly, Edwards Lifesciences, and McKesson, partially offset by trims to Boston Scientific. This is a classic institutional rotation into earnings-resilient cash flows as the cycle matures.

Finance and Consumer Discretionary are the losers of the quarter. Finance drops from 11.35% to 9.67% as JPMorgan, Bank of America, and American Express are cut back. Consumer Discretionary slips from 14.7% to 13.1%, with reductions in Amazon, Walmart, Sherwin-Williams, Spotify, and AutoZone overshadowing adds in TJX, United Rentals, and BKR.

Meanwhile, they are quietly bulking up in Energy and infrastructure. Energy climbs from 2.69% to 3.48% via sizeable TTE and EQT increases; Basic Materials and Utilities also tick up, while telecom exposure jumps from 0.6% to 1.29% on the Arista build. Real Estate stays roughly flat at 4.45%, but within that bucket they’re sneaking in more transaction exposure via a doubled Mastercard stake, even though it shows up in the data as Real Estate.

Net-net, Dz Bank is rotating from generalized growth and financial cyclicals towards health care, energy, semis, and network infrastructure — sectors that can still grow through a choppier macro tape and a higher-for-longer rate backdrop.

This is not the posture of a manager calling for recession or fleeing risk; it’s the posture of one who sees the easy market beta phase behind us and wants more control over where the earnings growth actually comes from.

On one side of the barbell, they’ve built a diversified, scaled health care complex spanning big pharma, GLP‑1s, devices, and distributors. That should dampen drawdowns if consumer and financial earnings wobble, and it gives them multiple shots on goal beyond any single therapeutic hype cycle.

On the other side, they’re tripling down on the infrastructure layer of AI and digital transformation. NVIDIA, Arm, Broadcom, AMAT, Arista, Cloudflare, and Meta form a coherent thesis: capex-heavy AI and cloud build-outs will persist even if top-line GDP slows, and the bottlenecks will be silicon, bandwidth, and secure delivery, not demand.

Layered over that is a clear macro expression: more Energy (TTE, EQT), more industrial and construction leverage (URI, CAT, PWR, FTAI, AMRZ), and a modest uptick in Utilities. That’s consistent with a world where inflation doesn’t vanish and physical infrastructure spending — from power grids to data centers to equipment fleets — remains elevated.

Going forward, watch whether they continue to bleed down money-center banks and broad consumer names to fund this health care/AI/hard-asset axis. If they do, Dz Bank’s book will look less like a generic large-cap growth clone and more like a targeted portfolio of companies that either control critical chokepoints in an AI-first economy or deliver essential services regardless of the macro weather.